The stock of Aimmune Therapeutics Inc (NASDAQ:AIMT) is a huge mover today! About 319,986 shares traded hands or 113.00% up from the average. Aimmune Therapeutics Inc (NASDAQ:AIMT) has risen 18.57% since April 4, 2016 and is uptrending. It has outperformed by 17.48% the S&P500.
The move comes after 6 months positive chart setup for the $767.34M company. It was reported on Nov, 4 by Barchart.com. We have $29.42 PT which if reached, will make NASDAQ:AIMT worth $475.75 million more.
Aimmune Therapeutics Inc (NASDAQ:AIMT) Ratings Coverage
Out of 4 analysts covering Aimmune Therapeutics (NASDAQ:AIMT), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aimmune Therapeutics has been the topic of 5 analyst reports since August 31, 2015 according to StockzIntelligence Inc. The company was initiated on Monday, September 26 by JMP Securities. The rating was initiated by Credit Suisse with “Outperform” on Monday, August 31. The firm has “Overweight” rating by Piper Jaffray given on Tuesday, November 17. The stock of Aimmune Therapeutics Inc (NASDAQ:AIMT) earned “Buy” rating by Bank of America on Monday, August 31. Piper Jaffray initiated the shares of AIMT in a report on Monday, August 31 with “Overweight” rating.
According to Zacks Investment Research, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California.”
More notable recent Aimmune Therapeutics Inc (NASDAQ:AIMT) news were published by: Streetinsider.com which released: “NestlÃ© Health Science to Make $145M Investment in Aimmune Therapeutics (AIMT)” on November 04, 2016, also Businesswire.com with their article: “Aimmune Therapeutics Announces COO Transition” published on October 09, 2015, Marketwatch.com published: “/quotes/zigman/3870025/realtime” on July 12, 2015. More interesting news about Aimmune Therapeutics Inc (NASDAQ:AIMT) were released by: Businesswire.com and their article: “Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences” published on October 31, 2016 as well as Businesswire.com‘s news article titled: “Aimmune Therapeutics Completes and Exceeds North American Enrollment Target …” with publication date: September 20, 2016.
AIMT Company Profile
Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, incorporated on June 24, 2011, is a clinical-stage biopharmaceutical firm developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.